National Institutes of Health logo
National Institutes of Health

Translational Transplantation Tolerance Cooperative Study Group

Funds a multi-center group translating transplant tolerance regimens toward the clinic, so grafts survive without lifelong immune-suppressing drugs.

ScheduledNational Institutes of HealthUnited States

Organ transplant recipients normally take immune-suppressing drugs for life, with all the infection and cancer risk that carries. This group exists to make that unnecessary, by getting tolerance regimens out of the lab and into people.

The goal is stated directly: facilitate clinical translation of safe and effective transplant tolerance regimens that achieve long-term graft survival without life…

Development, optimisation and evaluation of approaches to induce and maintain immune tolerance to allogeneic organ transplants, tested in translationally relevant models, aimed at clinical translation of tolerance regimens that sustain long-term graft survival without lifelong immunosuppressive drugs.

CycleiHow often this grant runs — e.g. annually, on a rolling basis, or a one-off call.One-off
Next deadlineiThe next date applications are due. Rolling means you can apply any time.21 May 2027
Decision timeiTypical time from the deadline to the funder's decision.26 weeks
Project durationiHow long the funded work is expected to run.—
Award typeiThe form of funding — grant, equity, loan, tax credit, etc.Cooperative agreement
Match fundingiThe share of project costs you must cover yourself. 0% = fully funded.—
Funding pooliThe total budget available across all awards in this round.$10.5M

Sign up free to see the funding breakdown

Sign up free to see the industries in scope

Sign up free to see the full eligibility

Sign up free to see how to apply

Sign up free to see what you submit

Sign up free to see how they score you

Sign up free to see the timeline

Sign up free to see where teams trip up

Last verified: 25 Aug 2026Funder reference: RFA-AI-28-010Source: www.grants.gov